SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Nashel DJ. Is atherosclerosis a complication of long-term corticosteroid treatment? [review]. Am J Med 1986; 80: 9259.
  • 2
    Davis JM 3rd, Maradit-Kremers H, Gabriel SE. Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect? J Rheumatol 2005; 32: 185662.
  • 3
    Girod JP, Brotman DJ. Does altered glucocorticoid homeostasis increase cardiovascular risk? [review]. Cardiovasc Res 2004; 64: 21726.
  • 4
    Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? Postgrad Med J 1994; 70: 86370.
  • 5
    Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids [review]. Pharmacol Ther 2002; 96: 2343.
  • 6
    Limbourg FP, Huang Z, Plumier JC, Simoncini T, Fujioka M, Tuckermann J, et al. Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids [published erratum appears in J Clin Invest 2003;111:759]. J Clin Invest 2002; 110: 172938.
  • 7
    Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, Rebsamen MC, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002; 8: 4739.
  • 8
    Voisard R, Seitzer U, Baur R, Dartsch PC, Osterhues H, Hoher M, et al. Corticosteroid agents inhibit proliferation of smooth muscle cells from human atherosclerotic arteries in vitro. Int J Cardiol 1994; 43: 25767.
  • 9
    Sakai M, Biwa T, Matsumura T, Takemura T, Matsuda H, Anami Y, et al. Glucocorticoid inhibits oxidized LDL-induced macrophage growth by suppressing the expression of granulocyte/macrophage colony-stimulating factor. Arterioscler Thromb Vasc Biol 1999; 19: 172633.
  • 10
    Giugliano GR, Giugliano RP, Gibson CM, Kuntz RE. Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol 2003; 91: 10559.
  • 11
    Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 76470.
  • 12
    Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts AC, Leufkens HG, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004; 90: 85965.
  • 13
    Bruce IN. ‘Not only…but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus [review]. Rheumatology (Oxford) 2005; 44: 1492502.
  • 14
    Hall FC, Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? [review]. Rheumatology (Oxford) 2005; 44: 147382.
  • 15
    Del Rincon I, O'Leary DH, Haas RW, Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004; 50: 381322.
  • 16
    Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Ines LB, et al. Safety of low-dose glucocorticoid therapy in rheumatoid arthritis: published evidence and prospective trial data [review]. Ann Rheum Dis 2006; 65: 28593.
  • 17
    Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 72232.
  • 18
    Manzi S, Wasko MC. Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 2000; 59: 3215.
  • 19
    Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis [review]. N Engl J Med 2002; 347: 26171.
  • 20
    Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 2005; 32: 6573.
  • 21
    Melton LJ 3rd. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996; 71: 26674.
  • 22
    Maradit Kremers H, Crowson CS, Gabriel SE. Rochester Epidemiology Project: a unique resource for research in the rheumatic diseases [review]. Rheum Dis Clin North Am 2004; 30: 81934, vii.
  • 23
    Maradit Kremers H, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Use of physician services in a population-based cohort of patients with polymyalgia rheumatica over the course of their disease. Arthritis Rheum 2005; 53: 395403.
  • 24
    Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Olivieri I, Hunder GG. The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 2000; 27: 217984.
  • 25
    Doran MF, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE. Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 2002; 29: 16947.
  • 26
    Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 11228.
  • 27
    Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 2003; 349: 237980.
  • 28
    Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus [letter] [published erratum appears in N Engl J Med 2006;355:1746]. N Engl J Med 2003; 349: 2399406.
  • 29
    Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol 1999; 26: 256271.
  • 30
    Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24: 44551.
  • 31
    Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C, Gonzalez-Gay MA. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82: 40713.
  • 32
    Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Ollier WE, et al. Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2004; 33: 2318.
  • 33
    Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Vidan J, et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003; 114: 64752.
  • 34
    Davis J, Maradit Kremers H, Crowson C, Nicola PJ, Ballman KV, Therneau TM, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis. Arthritis Rheum. In press.
  • 35
    Asai K, Funaki C, Hayashi T, Yamada K, Naito M, Kuzuya M, et al. Dexamethasone-induced suppression of aortic atherosclerosis in cholesterol-fed rabbits: possible mechanisms. Arterioscler Thromb 1993; 13: 8929.
  • 36
    Yamada K, Naito M, Hayashi T, Asai K, Yoshimine N, Iguchi A. Effects of dexamethasone on migration of human monocytes in response to oxidized β: very low density lipoprotein. Artery 1993; 20: 25367.
  • 37
    Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22 Suppl 4: 6A13.
  • 38
    Gran JT, Myklebust G, Wilsgaard T, Jacobsen BK. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology (Oxford) 2001; 40: 123842.